Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab

BACKGROUND: With no approved long-term prophylaxis (LTP) for the prevention of hereditary angioedema (HAE) attacks in Hong Kong, patients rely on compassionate use programs and drug trials. Moreover, studies regarding the use and efficacy of LTP in Asia are lacking. OBJECTIVES: Our aim was to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Jane C.Y., Chiang, Valerie, Lam, Dorothy L.Y., Lee, Elaine, Lam, Ki, Au, Elaine Y.L., Li, Philip H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679768/
https://www.ncbi.nlm.nih.gov/pubmed/38024849
http://dx.doi.org/10.1016/j.jacig.2023.100166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679768/
https://www.ncbi.nlm.nih.gov/pubmed/38024849
http://dx.doi.org/10.1016/j.jacig.2023.100166

Ejemplares similares